Over the years, the clinical role of minimally invasive procedures, endoscopy and chromoscopy, serum and histologic biomarkers, and epidemiology have evolved and intertwined enabling early detection, treatment and management of cancers, premalignant lesions, and conditions of high cancer risk. These interventions and measures have positively impacted survival rates of esophageal and stomach cancers, which now presenting with roughly 21% and 33% survival rates over five years according to the most recent SEER database statistics.
The property management, investigation, and follow- up of premalignant lesions and superficial neoplasms in the esophagus and stomach are still essential, as they have the potential to further improve the survival rates of patients, and to reduce local and systemic recurrence by allowing earlier curative interventions.
This Research Topic invites submissions of basic, translational and clinical studies which cover the role of premalignant and high-risk factors in the development of esophageal and gastric cancer, encompassing but not limited to; Barrett oesophagus, achalasia, chronic gastritis, gastroesophageal reflux disorder (GERD), esophagitis of varying types (e.g infectious, drug induced, eosinophilic etc.), and esophageal stenosis due to ingestion of corrosive agents.
The clinical investigation, management, and follow-up of these conditions should be discussed with regard to their management or curative treatment, to subsequently prevent their development into cancer diagnoses and optimize patient outcomes. Manuscript submissions demonstrating real-world utilizations of investigated management methods, or validated suggestions of how current treatment recommendations can be updated or amended are welcome within this Research Topic.
Important Note: Manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) will not be accepted in any of the sections of Frontiers in Oncology.
Over the years, the clinical role of minimally invasive procedures, endoscopy and chromoscopy, serum and histologic biomarkers, and epidemiology have evolved and intertwined enabling early detection, treatment and management of cancers, premalignant lesions, and conditions of high cancer risk. These interventions and measures have positively impacted survival rates of esophageal and stomach cancers, which now presenting with roughly 21% and 33% survival rates over five years according to the most recent SEER database statistics.
The property management, investigation, and follow- up of premalignant lesions and superficial neoplasms in the esophagus and stomach are still essential, as they have the potential to further improve the survival rates of patients, and to reduce local and systemic recurrence by allowing earlier curative interventions.
This Research Topic invites submissions of basic, translational and clinical studies which cover the role of premalignant and high-risk factors in the development of esophageal and gastric cancer, encompassing but not limited to; Barrett oesophagus, achalasia, chronic gastritis, gastroesophageal reflux disorder (GERD), esophagitis of varying types (e.g infectious, drug induced, eosinophilic etc.), and esophageal stenosis due to ingestion of corrosive agents.
The clinical investigation, management, and follow-up of these conditions should be discussed with regard to their management or curative treatment, to subsequently prevent their development into cancer diagnoses and optimize patient outcomes. Manuscript submissions demonstrating real-world utilizations of investigated management methods, or validated suggestions of how current treatment recommendations can be updated or amended are welcome within this Research Topic.
Important Note: Manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) will not be accepted in any of the sections of Frontiers in Oncology.